186 related articles for article (PubMed ID: 24124608)
1. GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.
Lee EJ; Kang G; Kang SW; Jang KT; Lee J; Park JO; Park CK; Sohn TS; Kim S; Kim KM
PLoS One; 2013; 8(10):e77219. PubMed ID: 24124608
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
[TBL] [Abstract][Full Text] [Related]
5. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.
Belinsky MG; Rink L; Flieder DB; Jahromi MS; Schiffman JD; Godwin AK; von Mehren M
Genes Chromosomes Cancer; 2013 Feb; 52(2):214-24. PubMed ID: 23109135
[TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST].
Kelly L; Bryan K; Kim SY; Janeway KA; Killian JK; Schildhaus HU; Miettinen M; Helman L; Meltzer PS; van de Rijn M; Debiec-Rychter M; O'Sullivan M;
PLoS One; 2013; 8(5):e64102. PubMed ID: 23717541
[TBL] [Abstract][Full Text] [Related]
8. Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors.
Matyakhina L; Bei TA; McWhinney SR; Pasini B; Cameron S; Gunawan B; Stergiopoulos SG; Boikos S; Muchow M; Dutra A; Pak E; Campo E; Cid MC; Gomez F; Gaillard RC; Assie G; Füzesi L; Baysal BE; Eng C; Carney JA; Stratakis CA
J Clin Endocrinol Metab; 2007 Aug; 92(8):2938-43. PubMed ID: 17535989
[TBL] [Abstract][Full Text] [Related]
9. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
Zhi X; Zhou X; Wang W; Xu Z
PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
[TBL] [Abstract][Full Text] [Related]
10. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA.
Beadling C; Patterson J; Justusson E; Nelson D; Pantaleo MA; Hornick JL; Chacón M; Corless CL; Heinrich MC
Cancer Med; 2013 Feb; 2(1):21-31. PubMed ID: 24133624
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
13. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
[TBL] [Abstract][Full Text] [Related]
14. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
15. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Corless CL; Schroeder A; Griffith D; Town A; McGreevey L; Harrell P; Shiraga S; Bainbridge T; Morich J; Heinrich MC
J Clin Oncol; 2005 Aug; 23(23):5357-64. PubMed ID: 15928335
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
17. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
18. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
[TBL] [Abstract][Full Text] [Related]
19. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
